

# Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023

February 21, 2023

GAITHERSBURG, Md., Feb. 21, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global vaccines company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2022 financial results and operational highlights on Tuesday, February 28, 2023, following the close of U.S. financial markets. Details of the event and replay are as follows:

Conference call details:

Date: February 28, 2023  
Time: 4:30 p.m. U.S. Eastern Standard Time (EST)  
Dial-in number: (833) 974-2381 (Domestic) or (412) 317-5774 (International)  
Webcast: [ir.novavax.com/events](https://ir.novavax.com/events)

- *Participants will be prompted to request to join the Novavax, Inc. call.*
- *To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.*

Replay details:

Date: Available starting at 7:30 p.m. EST, February 28, 2023 until 11:59 p.m. U.S. EST, March 7, 2023  
Dial-in number: (877) 344-7529 (Domestic) or (412) 317-0088 (International)  
Passcode: 1137418  
Webcast: [ir.novavax.com/events](https://ir.novavax.com/events), until May 28, 2023

## About Novavax

Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit [novavax.com](https://novavax.com) and [LinkedIn](#) for more information.

## CONTACTS

### Investors

Erika Schultz  
240-268-2022  
[ir@novavax.com](mailto:ir@novavax.com)

### Media

Ali Chartan  
240-720-7804  
[media@novavax.com](mailto:media@novavax.com)

SOURCE Novavax, Inc.

Image not found or type unknown